Life Cycle Management Strategies - Optimizing revenues and defending generic competition is a new market research publication announced by Reportstack. This report discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on.

Companies mentioned in the report are AbbVie, Actavis, AstraZeneca, Cipla, Gilead, GlaxoSmithKline, Gleevec, Janssen, MannKind, Merck, Novartis, Orexo, Otsuka, Pfizer, Roche, Salix Pharmaceuticals, Sanofi-Aventis, Solvay, Teva and Vifor Pharma.

Complete report with TOC available @ Life Cycle Management Strategies - Optimizing revenues and defending generic competition.

Scope

- Introduction of LCM and product life cycle- Objectives of LCM and factors impacting the choice of strategies- LCM strategies depending on the way of approach- Impact of LCM strategies on sales and growth trend of selected products- Patent term extension and market exclusivity in the US and Europe- LCM strategies of pipeline drugs of key players- Keys to successful implementation of LCM strategies

Key Reasons to Purchase

- Identify the key LCM strategies used by most of the pharmaceutical companies- Analyze the strategies to increase lifecycle and revenues of a drug- Gain an understanding on the implementation of multiple strategies for a single product by including case studies- Understand the operational pipeline strategies of key players"

Contact:

Debora WhiteManager - Marketing debora@reportstack.comPh: +1-888-789-6604Reportstack Market Research    ###